ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

MICARDIS
CHF and arrhythmias
Hypertension
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

MICARDIS Rx

Generic Name and Formulations:
Telmisartan 20mg, 40mg, 80mg; tabs.

Company:
Boehringer Ingelheim Pharmaceuticals

Therapeutic Use:

Indications for MICARDIS:

Cardiovascular (CV) risk reduction in patients ≥55 years of age at high risk of developing major CV events who are unable to take ACE inhibitors.

Adult:

80mg once daily. Monitor BP; adjustments to meds that lower BP may be needed.

Children:

Not recommended.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting therapy or monitor closely. Severe CHF. Biliary obstruction. Hepatic or renal impairment. Renal artery stenosis. Dialysis (monitor for orthostatic hypotension). Neonates. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Interactions:

See Contraindications. Concomitant ACE inhibitors (eg, ramipril): not recommended. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May potentiate digoxin. Monitor lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Adverse Reactions:

Back pain, upper respiratory tract infection, sinusitis, diarrhea, pharyngitis, angioedema; intermittent claudication, skin ulcer; rare: rhabdomyolysis.

How Supplied:

Tabs—3 x 10 (blister cards)

Indications for MICARDIS:

Hypertension.

Adult:

Not volume-depleted: initially 40mg once daily; usual range 20–80mg/day. Salt/volume depleted: monitor closely or consider reduced dose. May add diuretic if insufficient response at 80mg/day.

Children:

Not recommended.

Contraindications:

Concomitant aliskiren in patients with diabetes.

Warnings/Precautions:

Fetal toxicity may develop; discontinue if pregnancy is detected. Correct hypovolemia before starting therapy or monitor closely. Severe CHF. Biliary obstruction. Hepatic or renal impairment. Renal artery stenosis. Dialysis (monitor for orthostatic hypotension). Neonates. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.

Interactions:

See Contraindications. Concomitant ACE inhibitors (eg, ramipril): not recommended. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Concomitant aliskiren in renal impairment (CrCl <60mL/min): not recommended. Hyperkalemia with K+ supplements, K+ sparing diuretics, K+ containing salt substitutes. May potentiate digoxin. Monitor lithium levels. May be antagonized by, and renal toxicity potentiated by NSAIDs (including COX-2 inhibitors): monitor renal function in elderly and/or volume-depleted.

Pharmacological Class:

Angiotensin II receptor blocker (ARB).

Adverse Reactions:

Back pain, upper respiratory tract infection, sinusitis, diarrhea, pharyngitis, angioedema; rare: rhabdomyolysis.

How Supplied:

Tabs—3 x 10 (blister cards)

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs